Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Key lymphoma research from ASH 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.11
Views: 7203
Rating:

Prof Wyndham Wilson - National Cancer Institute, Maryland, USA

Prof Wyndham Wilson provides a comprehensive summary of the key lymphoma related research presented at the 2010 ASH congress in Florida. The first study discussed demonstrates that treating asymptomatic advanced stage follicular lymphoma patients with Rituxan (rituximab) rather than using the standard ‘watch and wait’ technique extends the time before the patient requires therapy. The second trial compared the Stanford V treatment regimen with ABVD treatment, which frequently involved radiotherapy, for patients with untreated advanced Hodgkin’s lymphoma. This study revealed that Stanford V was not superior to ABVD and clinicians must now decide if the shorter treatment time of Stanford V compensates for the additional toxicities associated with radiotherapy. The third study found that patients under 60 with diffuse large B-cell lymphoma had a significantly greater event free survival, progression free survival, disease free survival and overall survival than those treated with R-CHOP. Prof Wilson discusses the promising results of a study of the HDAC inhibitor romidepsin in peripheral T-cell lymphoma, a trial evaluating an anti-CCR4 monoclonal antibody known as KW-0761 in patients with adult T-cell lymphoma/leukaemia, a study looking to target CD30 protein cells with SGN-35 antibodies coupled to the cytotoxic monomethyl auristatin E in patients with Hodgkin’s lymphoma and a study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma.

This programme is supported by an educational grant from Mundipharma.

Related videos

follow us

Breast cancer epidemiology video


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation